Expert Insights

In part five of this series, Dr Agostinetto, Institut Jules Bordet, discusses safety measures in the HER2-low breast cancer treatment approach, adverse event management, and the importance of raising awareness by encouraging early detection...

In part 4 of this series, Elisa Agostinetto, MD, Institut Jules Bordet, discusses the challenges of technical assessment in the HER2-low breast cancer treatment space.

In part three of this series, Dr Agostinetto, Institut Jules Bordet, highlights future trial developments in the HER2-low breast cancer space such as DESTINY-breast-04, DESTINY-breast-06, and DEBBRAH study.

In part 2 of this series, Dr Agostinetto, Institut Jules Bordet, discusses several effective, promising agents in HER2-low breast cancer treatment.

In part one of this series, Elisa Agostinetto, MD, highlights the classification and distinguishing between HER2-positive and HER2-negative breast cancer.

In part two of this series, Dr Tward, MD, Huntsman Cancer Institute, discusses use of the Polaris test to prognosticate metastasis of men undergoing radiation therapy with prostate cancer, as well as ongoing efforts to further advance...

In part one of this series, Dr Jonathan Tward, MD, Huntsman Cancer Institute, reviews ongoing efforts to further advance personalized treatment in the prostate cancer space.

Erica Barnell, MD, PhD highlights Geneoscopy’s efforts to tackle healthcare disparities in pivotal colorectal cancer clinical trials utilizing a digital recruitment strategy.

​​​​​​​Erica Barnell, MD, PhD, discusses the importance of patient diversity and inclusion in the gastrointestinal clinical research space.

Constantine Tam, MD, overviews results from the phase 3 SEQUOIA study on zanubrutinib versus bendamustine-rituximab in patients with treatment-naïve CLL/SLL, presented at ASH 2021.